search
Back to results

Memokath® 044TW Stent for Treatment of Urethral Stricture

Primary Purpose

Urethral Stricture

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Memokath stenting
Sponsored by
Pnn Medical DK
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Urethral Stricture focused on measuring Memokath, Urethral stricture, urethral stent, Bulbar urethral stricture

Eligibility Criteria

21 Years - undefined (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria: Males > 21 years of age Recurrent stricture of the bulbar urethra: < 50 mm in length on urethrography; and which has a segment unable to accommodate a 16Fr flexible cystoscope Healthy tissue on both sides of stent Urinary flow in the abnormal range of the Siroky nomogram. Written informed consent obtained prior to participation in the study Patients must be available for all follow-up visits. Exclusion Criteria: Strictures: outside the bulbous urethra associated with, or suspected to be, urethral carcinoma secondary to pelvic distraction injuries Inability to enlarge the bulbar urethral stricture to > 26 Fr. Presence of any other urologic implant Presence of urethral diverticuli History of hypospadias repair Presence or prior history of balanitis xerotica obliterans. Uncontrolled bleeding disorder Active urinary tract infection Any urological condition that would be likely to require additional urethral instrumentation during the period of the investigation, including, but not limited to, benign prostatic hypertrophy requiring treatment; use of alpha blockers; active prostate cancer; an unevaluated elevated prostate-specific antigen (PSA); bladder malignancy; or any recurrent urinary stone formation. Serum creatinine > 2.0 mg/dl or evidence of progressive renal disease Concurrent participation in another clinical investigation Current illness that might confound the results of this investigation Inability to participate in all of the necessary study activities Inability or unwillingness to return for all required follow-up visits Inability or unwillingness to sign the patient informed consent document

Sites / Locations

  • Jack McAninch
  • Mississippi Urology
  • Cleveland Clinic
  • Bryn Mawr Urology
  • University Urological Associates
  • Devine-Tidewater Urology
  • Harborview Medical Center

Outcomes

Primary Outcome Measures

Stent/control effectiveness - urethral patency

Secondary Outcome Measures

Peak urinary flow rate
Re-intervention
Standard survey instruments (QOL, IPSS etc.)
Stent placement success
Stent removal success

Full Information

First Posted
December 23, 2005
Last Updated
November 17, 2009
Sponsor
Pnn Medical DK
search

1. Study Identification

Unique Protocol Identification Number
NCT00270504
Brief Title
Memokath® 044TW Stent for Treatment of Urethral Stricture
Official Title
Prospective, Randomized, Controlled, Multicenter Trial of the Memokath® 044TW Thermo-Expandable Stent for Maintaining Urethral Patency in Patients After Dilation or Internal Urethrotomy of Recurrent Stricture of the Bulbar Urethra
Study Type
Interventional

2. Study Status

Record Verification Date
December 2008
Overall Recruitment Status
Completed
Study Start Date
December 2002 (undefined)
Primary Completion Date
October 2009 (Actual)
Study Completion Date
November 2009 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Pnn Medical DK

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate if the placement of a temporary urethral stent for up to 12 months, following dilation or internal urethrotomy (cutting open), results in a higher rate of urethral patency during the first year of follow-up when compared to the control group that does not receive a stent.
Detailed Description
Patients with bulbar urethral stricture are 2:1 randomised for either urethral dilation or internal urethrotomy with (treatment group) or without (control group) subsequent stenting. All patients are followed for up to one year at 4-6 weeks, 3, 6, 9 and 12 months with visual assessment (urethroscopy) of urethral patency at the treated segment of the urethra. The stent is removed at one year. In case of premature stent removal the patient is also followed for up to one year unless further intervention is decided. Control patients are offered the stent treatment option if the stricture recurs within the observation period but this group is separately analysed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Urethral Stricture
Keywords
Memokath, Urethral stricture, urethral stent, Bulbar urethral stricture

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
92 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Device
Intervention Name(s)
Memokath stenting
Intervention Description
Urethral Stenting
Primary Outcome Measure Information:
Title
Stent/control effectiveness - urethral patency
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Peak urinary flow rate
Time Frame
Immediate
Title
Re-intervention
Time Frame
Short term
Title
Standard survey instruments (QOL, IPSS etc.)
Time Frame
15 mos
Title
Stent placement success
Time Frame
immediate
Title
Stent removal success
Time Frame
immediate

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males > 21 years of age Recurrent stricture of the bulbar urethra: < 50 mm in length on urethrography; and which has a segment unable to accommodate a 16Fr flexible cystoscope Healthy tissue on both sides of stent Urinary flow in the abnormal range of the Siroky nomogram. Written informed consent obtained prior to participation in the study Patients must be available for all follow-up visits. Exclusion Criteria: Strictures: outside the bulbous urethra associated with, or suspected to be, urethral carcinoma secondary to pelvic distraction injuries Inability to enlarge the bulbar urethral stricture to > 26 Fr. Presence of any other urologic implant Presence of urethral diverticuli History of hypospadias repair Presence or prior history of balanitis xerotica obliterans. Uncontrolled bleeding disorder Active urinary tract infection Any urological condition that would be likely to require additional urethral instrumentation during the period of the investigation, including, but not limited to, benign prostatic hypertrophy requiring treatment; use of alpha blockers; active prostate cancer; an unevaluated elevated prostate-specific antigen (PSA); bladder malignancy; or any recurrent urinary stone formation. Serum creatinine > 2.0 mg/dl or evidence of progressive renal disease Concurrent participation in another clinical investigation Current illness that might confound the results of this investigation Inability to participate in all of the necessary study activities Inability or unwillingness to return for all required follow-up visits Inability or unwillingness to sign the patient informed consent document
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gerry Jordan, MD
Organizational Affiliation
Sentara/Engineers and Doctors
Official's Role
Principal Investigator
Facility Information:
Facility Name
Jack McAninch
City
San Francisco
State/Province
California
ZIP/Postal Code
94110
Country
United States
Facility Name
Mississippi Urology
City
Jackson
State/Province
Mississippi
ZIP/Postal Code
39202
Country
United States
Facility Name
Cleveland Clinic
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Facility Name
Bryn Mawr Urology
City
Bryn Mawr
State/Province
Pennsylvania
ZIP/Postal Code
19010
Country
United States
Facility Name
University Urological Associates
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02904
Country
United States
Facility Name
Devine-Tidewater Urology
City
Norfolk
State/Province
Virginia
ZIP/Postal Code
23510
Country
United States
Facility Name
Harborview Medical Center
City
Seattle
State/Province
Washington
ZIP/Postal Code
98104
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Memokath® 044TW Stent for Treatment of Urethral Stricture

We'll reach out to this number within 24 hrs